Brickell Biotech, Inc. (BBI:NASDAQ) Investor Relations Material

Overview

Brickell Biotech is a clinical-stage pharmaceutical company that is working to develop innovative prescription therapeutics that can treat skin diseases. The company's focus is on debilitating skin conditions such as hyperhidrosis and other prevalent dermatological conditions. With its executive management team and board of directors bringing extensive experience in product development and global commercialization, Brickell aims to develop and commercialize innovative products that can be successful in the currently underserved dermatology global marketplace. The company's pipeline consists of potential novel therapeutics, and its strategy is to leverage its experience to in-license, acquire, develop, and commercialize innovative products.

Frequently Asked Questions

What is Brickell Biotech, Inc.'s ticker?

Brickell Biotech, Inc.'s ticker is BBI

What exchange is Brickell Biotech, Inc. traded on?

The company's shares trade on the NASDAQ stock exchange

Where are Brickell Biotech, Inc.'s headquarters?

They are based in Boulder, Colorado

How many employees does Brickell Biotech, Inc. have?

There are 11-50 employees working at Brickell Biotech, Inc.

What is Brickell Biotech, Inc.'s website?

It is https://brickellbio.com/

What type of sector is Brickell Biotech, Inc.?

Brickell Biotech, Inc. is in the Healthcare sector

What type of industry is Brickell Biotech, Inc.?

Brickell Biotech, Inc. is in the Biotechnology industry

Who are Brickell Biotech, Inc.'s peers and competitors?

The following five companies are Brickell Biotech, Inc.'s industry peers:

- Monash IVF Group Ltd

- Adaptive Biotechnologies

- Esperion Therapeutics

- Arcturus Therapeutics

- IGM Biosciences